DUBLIN--(BUSINESS WIRE)--The "Proteomics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
This report describes and evaluates the proteomic technologies that will play an important role in drug discovery, molecular diagnostics and practice of medicine in the post-genomic era - the first decade of the 21st century.
Proteomics will play an important role in medicine of the future which will be personalized and will combine diagnostics with therapeutics. Important areas of application include cancer (oncoproteomics) and neurological disorders (neuroproteomics). The text is supplemented with 44 tables, 29 figures and over 500 selected references from the literature.
The number of companies involved in proteomics has increased remarkably during the past few years. More than 300 companies have been identified to be involved in proteomics and 222 of these are profiled in the report with 442 collaborations.
The markets for proteomic technologies are difficult to estimate as they are not distinct but overlap with those of genomics, gene expression, high throughput screening, drug discovery and molecular diagnostics. Markets for proteomic technologies are analyzed for the year 2017 and are projected to years 2022 and 2027. The largest expansion will be in bioinformatics and protein biochip technologies. Important areas of application are cancer and neurological disorders.
Key Topics Covered:
Part I: Technologies & Markets
1. Basics of Proteomics
2. Proteomic Technologies
3. Protein biochip technology
4. Bioinformatics in Relation to Proteomics
5. Research in Proteomics
6. Pharmaceutical Applications of Proteomics
7. Application of Proteomics in Human Healthcare
10. Proteomics Markets
11. Future of Proteomics
Part II: Companies
13. Companies involved in developing proteomics
For more information about this report visit https://www.researchandmarkets.com/research/2tkr4z/proteomics?w=4